The expression levels of pro‐inflammatory and anti‐inflammatory cytokines and chemokines in blood serum of Alzheimer’s dementia patients: report from a pilot study in Kazakhstan

Aiym Kaiyrlykyzy, Gulnaz Zholdasbekova, Dinara Alzhanova, Farkhad Olzhayev, Aida Baibulatova, Andrey Tsoy, Sholpan Askarova

2022

Closed access Metadata (CSL-JSON)
DOI 10.1002/alz.069259
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Abstract Background Chronic peripheral inflammation is one of the critical factors contributing significantly to the development and progression of Alzheimer’s disease (AD). Human and animal studies strongly suggest that systemic inflammation, marked by changes in the peripheral profile of blood immune cells and blood levels of circulating pro‐inflammatory and anti‐inflammatory cytokines, can promote or even precede pro‐inflammatory conditions in the CNS. It has been reported that the levels of circulating pro‐inflammatory cytokines are increased while the levels of anti‐inflammatory cytokines are decreased in AD patients. However, despite increasing data supporting the association between abnormal peripheral inflammation and AD, no well‐established inflammatory biomarkers are currently available for AD. In this regards, we have studied an expanded spectrum of pro‐inflammatory and anti‐inflammatory cytokines and chemokines in the serum samples of the patients diagnosed with AD and compared them to those without cognitive impairment matched on age and gender. Methods We have simultaneously assayed cytokines and chemokines in the serum of AD patients (n=40) and normal controls (n=46) using MILLIPLEX Map Human Cytokine/Chemokine Magnetic Beas Panel on the Luminex xMAP technology according to the manufacturer’s protocol. The kit included the following 41 human cytokines and chemokines: EGF, IL‐12P70, IL‐13, IL‐15, IL‐17A, IL1RA, IP‐10, MCP‐1, MIP‐1α, MIP‐1β, RANTES, VEGF, FGF‐2, TGF‐α, FIT‐3L, Fractalkine, GRO, MCP‐3, MDC, PDGF‐AA, PDGF‐AB/BB, sCD40L, IL‐1α, IL‐1β, TNFα, G‐CSF, IFNγ, TNFβ, IL‐10, IL‐2, GM‐CSF, IL‐3, IL‐4, IL‐5, IL‐6, IL‐7, IL‐8, IL‐9, Eotaxin, IFNα2, and IL‐12P40. Results We have found IL‐12P40, IL‐9, IL‐7, GM‐CSF, IL‐10, IFNγ, IL‐1α, MCP‐3, FIT‐3L, IL‐17A, IL‐13, IL‐15, and IL‐12P70 were significantly higher in Alzheimer’s patients compared to controls. At the same time, cognitively healthy controls had higher concentrations of PDGF‐AB/BB, PDGF‐AA, RANTES, and FGF‐2 in the peripheral blood. We observed significant positive correlation between C‐reactive protein and IP‐10 (r=0.5), IL1RA (r=0.3), PDGF‐AA (r=0.3), IL‐10 (r=0.3), GRO (r=0.4), GCSF (r=0.3), PDGF‐AB/BB (r=0.3). Conclusion Studying the expression levels of pro‐inflammatory and anti‐inflammatory cytokines and chemokines in the blood serum of Alzheimer’s dementia patients is of considerable interest since it can potentially contribute to the discovery of new blood‐based biomarkers for earlier diagnosis of AD and development of the personalized treatment strategies.